| Laboratory Medicine and Pathobiology --- University of Toronto

Work in my laboratory focuses on the development of new testing that can be utilized in the clinical setting. We are using next generation sequencing and multiplex mutation testing to genotype blood and tissue samples from patients with diseases such as melanoma and lung cancer to better understand their underlying biology.

Horizontal Tabs Group

Research

Work in my laboratory focuses on the application of high throughput technologies -- for example, DNA and gene expression microarrays, tissue arrays, microRNA arrays and next generation sequencing. These technologies are applied to enhance our understanding of cancer biology. Specifically, we are interested in identifying biomarkers and genetic pathways that drive cancer initiation, progression and recurrence in two types of human cancer: Oral Squamous Cell Carcinoma (OSCC), and Mantle Cell Lymphoma (MCL). We are also focused on identifying pathways that are relevant to leukemia biology, mainly Acute Promyelocytic Leukemia (APL). More recently, I am also involved in high throughput and multiplex biomarker development and testing in Phase 1 trials, in order to enable a more rational approach to individualized therapy.

Publications

Tran B, Brown AMK, Bedard PL, Winquist E, Goss GD, Hotte SJ, Welch SA, Hirte HW, Zhang T, Stein LD, Ferretti V, Watt S, Jiao W, Ng K, Ghai S, Shaw P, Petrocelli T, Hudson TJ, NeeI BG, Onetto N, Siu LL, McPherson JD, Kamel-Reid S, Dancey JE. Feasibility of Real Time Next Generation Sequencing of Cancer Genes Linked to Drug Response: Results from a Clinical Trial. Int J Cancer, In Press, 2012.

Petrella TM, Tozer R, Belanger K, Savage KJ, Wong R, Smylie M, Kamel-Reid S, Tron V, Chen BE, Hunder NN, Hagerman L, Walsh W, Eisenhauer EA. Interleukin-21 has activity in patients with metastatic melanoma: A phase II Study. In press J of Clin Oncol.

Tran B, Dancey JE, Kamel-Reid S, McPherson JD, Bedard PL, Brown AM, Zhang T, Shaw P, Onetto N, Stein L, Hudson TJ, Neel BG, Siu LL. Cancer genomics: Technology, Discovery, and Translation. J Clin Oncol. 2012 Feb 20;30(6):647-60. Epub 2012 Jan 23.

Saieg MA, Geddie WR, Boerner SL, Liu N, Tsao M, Zhang T, Kamel-Reid S, da Cunha Santos G. The use of FTA cards for preserving unfixed cytological material for high-throughput molecular analysis. Cancer Cytopathol. 2012 Jan 24. doi: 10.1002/cncy.20205. [Epub ahead of print]

Kamel-Reid S, Zhang T, Persons DL, Nikiforova MN, Halling KC. Validation of KRAS Testing for Anti-EGFR Therapeutic Decisions for Patients With Metastatic Colorectal Carcinoma. Molecular Oncology Resource Committee of the College of American Pathologists. Arch Pathol Lab Med. 2012 Jan;136(1):26-32.

Jennings LJ, Smith FA, Halling KC, Persons DL, Kamel-Reid S. Design and Analytic Validation of BCR-ABL1 Quantitative Reverse Transcription Polymerase Chain Reaction Assay for Monitoring Minimal Residual Disease. Arch Pathol Lab Med. 2012 Jan;136(1):33-40.

Reis PP, Waldron L, Perez-Ordonez B, Pintilie M, Naranjo Galloni N, Xuan Y, Cervigne NK, Warner GC, Makitie AA, Simpson C, Goldstein D, Brown D, Gilbert R, Gullane P, Irish J, Jurisica I, Kamel-Reid S. A gene signature in histologically normal surgical margins is predictive of oral carcinoma recurrence. BMC Cancer 2011 Oct 11; 11-437.

Reis PP, Waldron L, Goswami RS, Xu W, Xuan Y, Perez-Ordonez B, Gullane P, Irish J, Jurisica I, Kamel-Reid S. mRNA transcript quantification in clinical archival samples using multiplexed, color-coded probes pairs. BMC Biotechnology. 2011 May 9; 11(1):46.

Chau NG, Perez-Ordonez B, Zhang K, Pham NA, Ho J, Zhang T, Ludkovski O, Wang L, Chen EX, Tsao MS, Kamel-Reid S, Siu LL. The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck Oncol. 2011 Feb 27;3:11.

da Cunha Santos G, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S, Squire J, Parulekar W, Moore MJ, Tsao MS. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer 2010 Dec 15;116(24):5599-607. doi:10.1002/cncr.25393.

Reis PP, Tomenson M, Cervigne NK, Machado J, Jurisica I, Pintilie M, Sukhai MA, Perez-Ordonez B, Grénman R Gilbert RW, Gullane PJ, Irish JC, Kamel-Reid S. Programmed cell death 4 loss increases tumor cell invasion and is regulated by miR-21 in oral squamous cell carcinoma. Molecular Cancer 2010 Sep 10; 9:238.

Goswami RS, Waldron L, Machado J, Cervigne NK, Xu W, Reis P, Jurisica I, Bailey DJ, Crump M, Kamel-Reid S. Optimization and analysis of a quantitative real-time PCR-based technique to determine microRNA expression in formalin-fixed paraffin-embedded samples. BMC Biotechnol. Jun 23; 10(1):47, 2010.

Machado J, Reis PP, Zhang T, Simpson C, Xu W, Perez-Ordonez B, Goldstein DP, Brown D, Gilbert R, Gullane P, Irish J, Kamel-Reid S. Low Prevalence of Human Papillomavirus in Oral Cavity Carcinomas. Head and Neck Oncology Mar 12; 2(1):6, 2010.

Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K, Messner HA, Lipton JH. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res. 2009 Jul 15;15(14):4750-8, 2009.

Barker E, Cervigne NK, Reis PP, Weinreb I, Irish J, Kamel-Reid S. microRNA evaluation of unknown primary lesions in the head and neck. Molecular Cancer 23(8):127, 2009)

Cervigne NK, Reis, P, Machado J, Sadikovic B, Bradley G, Galloni NN, Pintilie M, Jurisica I, Perez-Ordonez B, Gilbert R, Gullane P, Irish JC, Kamel-Reid S. Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. Hum. Mol. Genet. 18(24): 4818-4829, 2009.

Jones D, Kamel-Reid S, Bahler D, Dong H, Elenitoba-Johnson K, Press R, Quigley N, Rothberg P, Sabath D, Viswanatha D, Weck K, Zehnder J. Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology. J Mol Diagn. Jan;11(1):4-11, 2009.

Reis PP, Bharadwaj RR, Machado J, Macmillan C, Pintilie M, Sukhai MA, Perez-Ordonez B, Gullane P, Irish J, Kamel-Reid S. Claudin 1 overexpression increases invasion and is associated with aggressive histological features in oral squamous cell carcinoma. Cancer Dec 1;113(11):3169-80, 2008.

Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kamel-Reid S, Seymour L, Shepherd FA, Tsao MS; National Cancer Institute of Canada Clinical Trials Group Study BR.21. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 26(26):4268-75, 2008.

Agulnik M, da Cunha Santos G, Hedley D, Nicklee T, Dos Reis PP, Ho J, Pond GR, Chen H, Chen S, Shyr Y, Winquist E, Soulieres D, Chen EX, Squire JA, Marrano P, Kamel-Reid S, Dancey J, Siu LL, Tsao MS. (2007) Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol. 25(16):2184-90, 2007

Search form

You are here

Horizontal Tabs Group